Stereotaxis Introduces New Electrophysiology Platform: Epoch™

The Stereotaxis Epoch™ Platform is Designed to Increase Efficiency in Electrophysiology Procedures with a Fully-Remote, Networked and Modular Robotic and Magnetic Solution

News provided by

Stereotaxis, Inc.

Apr 27, 2011, 06:30 ET

ST. LOUIS, April 27, 2011 /PRNewswire/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announces the introduction of its new Stereotaxis Epoch™ platform, a comprehensive solution for any electrophysiology lab which combines the recognized benefits of remote magnetic catheter control, the efficiency of remote robotic device manipulation, and the power of the Odyssey platform, enabling highly sophisticated procedural data integration and transmission. The Epoch™ platform will be unveiled at the annual Heart Rhythm Society meeting May 5-7, 2011 in San Francisco, CA.

The Stereotaxis Epoch solution is the beginning of a new modular platform designed to meet the broad range of clinical needs physicians face today and in the future. Building on the strength of Magnetic Navigation's exceptional safety profile and significant radiation reduction, the Epoch platform features the latest technological breakthroughs in Magnetic Navigation, which will lead to faster, more efficient, and dynamic magnetic catheter control. In addition, the Epoch platform will seamlessly integrate Stereotaxis' Vdrive™ mechanical robotic platform for remote manipulation of a growing array of devices, such as loop diagnostic catheter and sheath.

The Epoch solution delivers value well beyond the lab with the power of Stereotaxis' Odyssey™ solution–an unprecedented offering which integrates the complex array of clinical data into synchronized, high-definition view delivering real-time clinical information anywhere at physicians' fingertips. The Odyssey solution empowers hospital executives to drive initiatives which improve care, enhance performance, and increase referrals and market services throughout global communities.

"We are excited to introduce our Epoch solutions to the EP market as we are committed to developing solutions that meet the most critical needs of our customers, while supporting any preferred clinical treatment technique," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "Early feedback from key opinion leaders suggests that the Epoch platform enables us to deliver a much more efficient and enhanced EP workflow while maintaining our excellent profile in safety, radiation reduction and clinical outcome."

Stereotaxis expects that the Stereotaxis Epoch solutions will significantly reduce procedure time for all types of robotic-assisted EP procedures, especially for atrial fibrillation ablation procedures. In addition, user learning curve will be accelerated as a result of automated scripting of expert users' navigation techniques. Furthermore, labs equipped with the Vdrive module can benefit from optimized and full remote navigation and control of devices such as loop diagnostic catheters and sheaths.

While customers in EU markets already have commercial access to the Vdrive module, Vdrive is currently under FDA 510(k) review prior to its commercial availability in the U.S. market.

About Stereotaxis www.stereotaxis.com www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. The Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey™ Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. The Odyssey™ solution then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.